A Farewell To Bad News feat Ken Klippenstein (E278)
QAA Podcast
Vertex's Bold $5 Billion Move
This chapter explores Vertex Pharmaceuticals' substantial acquisition of Alpine Immune Sciences, focusing on its strategic importance and the potential impact on kidney autoimmune disease treatments. The discussion also highlights the risks involved with the acquisition and touches on unexpected profits from gold sales in retail.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
